Chief Financial Officer and Treasurer · Terns Pharmaceuticals, Inc. (TERN)

Andrew Gengos

FY2025 is the first fiscal year CompBrief holds for Andrew Gengos as a named executive officer of Terns Pharmaceuticals; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$2,621,738

Salary $434,807Stock awards $0Bonus $8,691

2nd of 3 named executive officers at Terns Pharmaceuticals by FY2025 total.

3 named officers on file for Terns Pharmaceuticals, FY2025

Andrew Gengos’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Terns Pharmaceuticals’s whole pay program stands against its peers

  • Terns Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on TERN→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 27, 2026 (10-K/A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Andrew Gengos’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Andrew Gengos compensation by year

Terns Pharmaceuticals Summary Compensation Table · the one fiscal year held
In US dollars, as Terns Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$434,807
Bonus$8,691
Stock awards$0
Option awards$1,912,202
Non-equity incentive$252,038
Pension and deferred compensation$0
All other$14,000
Total$2,621,738

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Terns Pharmaceuticals, Inc. 10-K/A filed April 27, 2026, accession 0001193125-26-182140, and prior-year filings.

How this page was built: the Terns Pharmaceuticals, Inc. filed document, accession 0001193125-26-182140. Every figure is read from that document and cited to the page and table it appears in. Filed April 27, 2026.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
Option750,000—$3.73

Per the Outstanding Equity Awards at Fiscal Year-End table in Terns Pharmaceuticals, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

4 Form 4 lines since the FY2025 proxy (filed April 27, 2026)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-05-05Disposition to the issuer—68,750$53.000
2026-05-05Disposition to the issuer derivative—750,000—0
2026-05-05U—40,503$53.000
2026-05-05Disposition to the issuer derivative—137,500—0

The 4 most recent of 4 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Terns Pharmaceuticals’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Amy BurroughsChief Executive Officer and Director$4,589,929
Andrew Gengos · this pageChief Financial Officer and Treasurer$2,621,738
Emil KuriakoseChief Medical Officer$2,361,216

The full Terns Pharmaceuticals compensation record

free company brief

This page is one person within Terns Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Terns Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Andrew Gengos's compensation dossier · One-time report. No refunds.